These findings suggest that miR-155 may function as an oncogene in ALL [19] and that miR-155 may be targeted in the future to treat ALL by regulating the CBL-mediated IRF4/CDK6 axis (Figure 1). Here, CDK6 is linked to acute lymphoblastic leukemia.